Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Ogasawara

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Clinical Pharmacology in Drug Development|February 2, 2019
Use of Population Pharmacokinetic Analyses Among FDA-Approved BiologicsKen Ogasawara, G Caleb Alexander
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 5, 2005
[Serum amyloid A and LDL complex]Shinichi Mashiba, Kazuo Uchida, Ken Ogasawara
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 1, 2012
Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimusChirag G Patel, Ken Ogasawara, Fatemeh Akhlaghi
Journal of Pharmaceutical Sciences|July 27, 2025
Integrative population pharmacokinetic modeling of two BCMA-targeted and one CD19-targeted CAR-T therapies using full Bayesian inference with a student's t-based M3 censoring approach for robust handling of outliers and BLQ dataYiming Cheng, Hongxiang Hu, Ken Ogasawara, et al.
Atherosclerosis|April 12, 2002
Increased level of advanced oxidation protein products in patients with coronary artery diseaseHideaki Kaneda, Junichi Taguchi, Ken Ogasawara, et al.
Journal of Cardiology|March 9, 2010
Association of the manganese superoxide dismutase polymorphism with vasospastic angina pectorisHajime Fujimoto, Hisae Kobayashi, Ken Ogasawara, et al.
Therapeutic Drug Monitoring|January 24, 2014
Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitusIleana A Ionita, Ken Ogasawara, Reginald Y Gohh, et al.
Cancer Chemotherapy and Pharmacology|August 25, 2019
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemiaKen Ogasawara, Simon Zhou, Gopal Krishna, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2020
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjectsKen Ogasawara, Christine Xu, Vanaja Kanamaluru, et al.
Clinical Therapeutics|December 24, 2017
Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved BiologicsKen Ogasawara, Christopher D Breder, Dora H Lin, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology in Drug Development|February 2, 2019
Use of Population Pharmacokinetic Analyses Among FDA-Approved BiologicsKen Ogasawara, G Caleb Alexander
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 5, 2005
[Serum amyloid A and LDL complex]Shinichi Mashiba, Kazuo Uchida, Ken Ogasawara
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 1, 2012
Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimusChirag G Patel, Ken Ogasawara, Fatemeh Akhlaghi
Journal of Pharmaceutical Sciences|July 27, 2025
Integrative population pharmacokinetic modeling of two BCMA-targeted and one CD19-targeted CAR-T therapies using full Bayesian inference with a student's t-based M3 censoring approach for robust handling of outliers and BLQ dataYiming Cheng, Hongxiang Hu, Ken Ogasawara, et al.
Atherosclerosis|April 12, 2002
Increased level of advanced oxidation protein products in patients with coronary artery diseaseHideaki Kaneda, Junichi Taguchi, Ken Ogasawara, et al.
Journal of Cardiology|March 9, 2010
Association of the manganese superoxide dismutase polymorphism with vasospastic angina pectorisHajime Fujimoto, Hisae Kobayashi, Ken Ogasawara, et al.
Therapeutic Drug Monitoring|January 24, 2014
Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitusIleana A Ionita, Ken Ogasawara, Reginald Y Gohh, et al.
Cancer Chemotherapy and Pharmacology|August 25, 2019
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemiaKen Ogasawara, Simon Zhou, Gopal Krishna, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2020
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjectsKen Ogasawara, Christine Xu, Vanaja Kanamaluru, et al.
Clinical Therapeutics|December 24, 2017
Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved BiologicsKen Ogasawara, Christopher D Breder, Dora H Lin, et al.
Pageof 10